IPO - ReShape Lifesciences Inc.

Form Type: S-1/A

Filing Date: 2025-02-14

Corporate Action: Ipo

Type: Update

Accession Number: 000110465925013174

Filing Summary: ReShape Lifesciences Inc. is amending its registration statement under the Securities Act of 1933 to allow for the offering of up to 1,779,360 units, each consisting of one share of common stock and one warrant to purchase one share of common stock. The offering price is assumed to be $2.81 per Unit, based on recent closing prices of their common stock on Nasdaq. The Warrants will have specific conditions for exercise, including approval by stockholders and are subject to a potential one-time reset of the exercise price. Additionally, the company is allowing for pre-funded warrants for certain purchasers. This document indicates the company's strategic goal of providing a portfolio of approved medical devices to manage obesity and metabolic diseases, which includes recent developments in their product offerings such as the Lap-Band 2.0 and the Obalon Balloon system. Financial updates highlight efforts to reduce operational costs while expanding product pipelines through strategic partnerships and a commitment to research and development.

Document Link: View Document

Form Type: S-1/A

Filing Date: 2025-02-14

Corporate Action: Ipo

Type: New

Accession Number: 000110465925014018

Filing Summary: ReShape Lifesciences Inc. filed an amendment to its Form S-1 registration statement, aiming to offer up to 1,779,360 units, with each unit consisting of one share of common stock and one warrant to purchase one share of common stock, at an assumed public offering price of $2.81 per unit. The offering includes up to 14,400,005 shares of common stock underlying the warrants. The registration statement allows for a potential 1-for-58 reverse stock split of the outstanding common stock, which was effective as of September 23, 2024. The company has made operational changes to improve its business metrics and reduce expenses. The filing indicates a strategy focused on product development, including the launch of the Lap-Band 2.0 FLEX, aimed at enhancing treatment options for obesity. The company also seeks to engage investors through an exclusive placement agent, Maxim Group LLC. This offering might help fund ongoing initiatives, including the development of new medical devices and expanding market access, particularly through strategic partnerships.

Document Link: View Document

Form Type: S-1MEF

Filing Date: 2025-02-14

Corporate Action: Ipo

Type: New

Accession Number: 000110465925014406

Filing Summary: ReShape Lifesciences Inc. has filed a registration statement with the SEC to register up to $9,152,802 in additional securities, which includes shares of common stock, pre-funded warrants, and warrants to purchase shares of common stock. This filing is pursuant to Rule 462(b), aiming to register additional securities that represent no more than 20% of the maximum aggregate offering price set forth in a prior effective registration statement. The company indicates it is a smaller reporting company and an emerging growth company. This registration statement will become effective upon filing and is intended to commence public sales as soon as practicable after its effective date.

Document Link: View Document

Form Type: CORRESP

Filing Date: 2025-02-12

Corporate Action: Ipo

Type: New

Accession Number: 000110465925012395

Filing Summary: ReShape Lifesciences Inc. is requesting the acceleration of its registration statement on Form S-1, File No. 333-283952, with the goal of having it declared effective at 4:00 p.m. Eastern Time on February 14, 2025. The request is made pursuant to Rule 461 of the Securities Act of 1933. The company has authorized its counsel, Fox Rothschild LLP, to modify or withdraw this request if necessary. ReShape Lifesciences has also requested a telephone notification regarding the effectiveness of the registration statement. The communication is signed by Paul F. Hickey, Chief Executive Officer of the company.

Document Link: View Document

Form Type: S-1/A

Filing Date: 2025-02-07

Corporate Action: Ipo

Type: Update

Accession Number: 000110465925010613

Filing Summary: On February 7, 2025, ReShape Lifesciences Inc. filed a revised S-1 registration statement, indicating significant disclosures regarding their planned initial public offering (IPO). The amendment addresses previous feedback from the SEC, providing updated financial information and revisions to their risk factors. The company continues to develop its medical technologies, including the Obalon Balloon System, which is primarily targeted for weight loss treatments. The document discusses the organization’s financial position, operational strategies, and potential market for investors. The filing outlines the intended use of proceeds from the IPO, expected to fund further research, operational expenses, and potential acquisitions or partnerships that align with its growth strategy. Detailed metrics on user adoption, revenue projections, and market penetration strategies are emphasized, showcasing the company's position in the competitive landscape of medical devices focused on obesity management.

Document Link: View Document

Form Type: S-1

Filing Date: 2025-01-21

Corporate Action: Ipo

Type: New

Accession Number: 000110465925004648

Filing Summary: ReShape Lifesciences Inc. filed a registration statement on Form S-1 with the SEC on January 21, 2025, for an initial public offering (IPO) of common stock. The offering is structured as a best-efforts sale, allowing the company to raise funds through the sale of up to a specified number of shares at an undecided price. The closing price of the common stock is referenced as having been determined on a recent date prior to the filing. The company intends to use the proceeds to finance operations and support growth strategies. The document outlines details regarding the offering, including risks associated with investing, placement agent fees, and market considerations. The final offering price is dependent on negotiations with investors, reflecting the company's market position and prospects, alongside potential discounts from the prevailing market prices.

Document Link: View Document